Retatrutide dosing sounds simple until you go looking for the schedule and run into two different versions floating around online, with nobody bothering to explain why they don’t match or which one you’re supposed to follow.
We pulled the real numbers straight from the trials instead of recycling whatever chart ranks first on Google, both titration ladders, what people lost in real pounds and not just percentages, and exactly where the FDA approval process stands as of today.
⚡ Quick Answer
Lilly’s newer Phase 3 trials start retatrutide at 2mg weekly and step up every 4 weeks toward a 4, 9, or 12mg maintenance dose. The earlier Phase 2 trial used a different ladder, starting at 1, 2, or 4mg and climbing toward 4, 8, or 12mg. At the top dose, people lost close to 70 pounds on average over about a year and a half in the largest trial. It is not FDA-approved yet, and pharmacies can’t compound it into a prescription, but it is sold as a research compound, and both titration ladders, the real numbers, and where to source it are all below.
🔍 Looking for 99% pure retatrutide? Everest Peptides catalogs it as GLP-3 RT, not the generic name, and every batch is third-party tested through Freedom Diagnostics with purity guaranteed above 99%. Sold in 10mg ($59.99 on sale), 20mg, and 30mg ($149.99 on sale) vials, and code BRAINFLOW takes another 10% off.
The Two Official Titration Schedules
Retatrutide is a once-weekly injection developed by Eli Lilly that activates three separate metabolic receptors at once, GIP, GLP-1, and glucagon, which is part of why the trials climb the dose so gradually. GLP-1 and GIP are the same receptors semaglutide and tirzepatide target, slowing digestion and reducing appetite. Glucagon is the addition unique to retatrutide, and it works differently, pushing the body to burn more energy at rest, which is part of why its trial results run ahead of the two approved drugs.
Two different escalation schedules have been used across Lilly’s clinical program, and knowing which one you are looking at matters.
The original Phase 2 schedule
The Phase 2 obesity trial, published in the New England Journal of Medicine, randomized 338 adults across several arms. One group stayed at a flat 1mg. The others escalated every 4 weeks toward a 4mg, 8mg, or 12mg maintenance dose, starting from either 2mg or 4mg depending on the arm. This is the ladder most dosage pages online still show, and it is the older of the two.
The current Phase 3 schedule
The ongoing Phase 3 TRIUMPH and TRANSCEND trials use a gentler, more gradual ladder. Everyone starts at 2mg weekly. From there, the dose steps up every 4 weeks, one step to reach 4mg, three steps (2, 4, 6mg) to reach 9mg, or four steps (2, 4, 6, 9mg) to reach 12mg. Lilly added the 6mg and 9mg rungs specifically because they smooth out the gastrointestinal side effects that show up during faster escalation.
Neither official schedule is a personal recommendation. Both are exactly what Lilly used under close medical supervision inside a controlled trial, a different setting from managing your own titration at home.
The protocol you’ll see most often
Search around and you’ll run into a third pattern that does not match either official trial exactly: 1mg, then 2mg, 4mg, 8mg, and finally 12mg, doubling at each step. It has become the default beginner protocol across vendor sites and community discussion, likely because doubling is easy to follow and lines up with how vials tend to get sold.
It is not the literal ladder either Lilly trial used to reach 12mg. Both official protocols start at 2mg or 4mg rather than 1mg. But it is close in spirit, it is once weekly the same way both trial schedules are, and it is what most people researching retatrutide dosing will run into first, so it is worth laying out clearly.
Every dose on this ladder is a once-weekly injection, on the same day each week if possible. Nothing about the pace is fixed in stone. Lilly’s own trials allowed participants to hold at a dose for an extra 2 to 4 weeks, or extend a step, when side effects needed more time to settle before moving up.
Reasons protocols commonly describe for slowing down include GI symptoms that are not easing, weight loss already happening faster than expected, or simply wanting more time to adjust. Reasons to speed past the standard 4-week pace are harder to find. Faster escalation is consistently linked to worse side effects and higher dropout in the trial data.
💡 Pro tip: Pick one day of the week and stay on it. Consistency matters more than which day, and it makes tracking how many weeks you have spent at a given dose far easier.
Trusted by BrainFlow Readers
Everest Peptides GLP-3 RT
It’s the source we trust for retatrutide. Every batch is third-party tested through Freedom Diagnostics with purity guaranteed above 99% by HPLC. 10mg runs $69.99, on sale for $59.99. 30mg runs $159.99, on sale for $149.99. Code BRAINFLOW takes another 10% off the sale price.
Shop GLP-3 RT → Save 10%Use code BRAINFLOW for 10% off. Sold for research use only.
Weight Loss by Dose
This is where retatrutide’s evidence base pulls ahead of most research compounds. The numbers below come directly from published results, not projections.
In the Phase 2 trial, at 48 weeks, average weight loss reached 8.7% at 1mg, 17.1% across the combined 4mg arms, 22.8% across the combined 8mg arms, and 24.2% at 12mg, against 2.1% on placebo. At the 12mg dose, every single participant lost at least 5% of their body weight, 93% lost at least 10%, and 83% lost at least 15%. The curve had not flattened out by week 48, meaning people were still losing weight when the trial ended.
The Phase 3 TRIUMPH-1 trial, which ran 80 weeks in adults without diabetes, reported average losses of 19.0% at 4mg, 25.9% at 9mg, and 28.3% at 12mg, against 2.2% on placebo. Just over 45% of people on the top dose lost at least 30% of their starting weight. In a longer follow-up group with a BMI of 35 or higher, the 12mg arm reached an average of 30.3% by week 104, about two years in.
Results varied somewhat by trial population. TRIUMPH-4, run in people with knee osteoarthritis, saw 28.7% average loss at 12mg. TRIUMPH-2, in people with both type 2 diabetes and obesity, topped out around 20.8%, lower than the non-diabetic trials, which tracks with how diabetes tends to blunt weight-loss response to this drug class generally.
Percentages are fine for comparing doses against each other, but they don’t tell you much about what happens to a real person. Some of the trials reported real pounds lost, not just percentages, so here is what that looked like.
Not every trial reported pounds, so here is a rough sense of what the 28.3% average from TRIUMPH-1 would mean at a few different starting weights, purely as a way to picture the number rather than a prediction for any specific person.
Notice the 250 lb row lands close to the real 70.3 lb figure TRIUMPH-1 reported. That is not a coincidence, it is roughly what the trial’s average participant weighed to start. Your own number will land somewhere on this curve, not exactly on it. Averages describe a group, not a guarantee for any one person in it.
Why Titration Moves So Slowly
Retatrutide’s half-life is roughly 6 days, which is exactly why it works as a once-weekly injection rather than a daily one. That half-life comes from a fatty acid chain attached to the peptide that lets it bind loosely to albumin in the blood, forming a slow-release depot under the skin, the same trick semaglutide and tirzepatide use.
It takes roughly 4 to 5 weeks of consistent dosing to reach steady state, the point where the drug stops building up and levels off. That is not a coincidence. Trial escalation happens on a 4-week clock specifically so each dose reaches its true steady-state effect before the next step up, which is also when gastrointestinal side effects are best judged, rather than reacting to a temporary spike.
The gradual pace exists almost entirely to manage nausea, vomiting, and diarrhea. Activating three metabolic receptors at once slows stomach emptying more than a single-receptor drug does, and rushing the climb is what triggers the worst of it.
The glucagon component adds a wrinkle the other two drugs do not have. On its own, glucagon tends to raise blood sugar, which is the opposite direction GLP-1 and GIP pull. The trials show the combined effect still nets out toward better blood sugar control, but it means the body is balancing two competing signals at once during the early weeks on any given dose, which is one more reason the step-ups happen slowly rather than all at once.
Side Effects by Dose
The clearest dose-by-dose safety data comes from TRANSCEND-T2D-1, a 40-week Phase 3 trial in people with type 2 diabetes. The numbers below compare 4mg, 9mg, and 12mg against placebo.
Most of these symptoms were mild to moderate and eased over time rather than getting worse. Skin tingling, formally called dysesthesia, is a side effect that shows up more with retatrutide than with single or dual-receptor drugs, running as high as 20.9% at the top dose in the TRIUMPH-4 trial.
In the trials, unresolved side effects were managed by holding a dose for an extra 2 to 4 weeks before stepping up again rather than pushing through.
💡 Pro tip: If nausea or vomiting has not started improving after about two weeks at a new dose, that is generally a sign to talk to a provider rather than wait it out. Anti-nausea medication can bridge the adjustment period, and holding or reversing a step is always an option.
Retatrutide vs Semaglutide vs Tirzepatide
All three work on the same general idea, mimicking gut hormones to reduce appetite, but they hit a different number of receptors. Semaglutide targets one, GLP-1. Tirzepatide targets two, GLP-1 and GIP. Retatrutide targets three, adding glucagon receptor activity on top of the other two.
A direct head-to-head between tirzepatide and semaglutide has already been run, and tirzepatide won clearly, 20.2% against 13.7% at 72 weeks. Retatrutide has never been tested head to head against either drug in the same trial.
Every retatrutide number above comes from a separate study, with its own population and duration, so treat the comparison as directional rather than a proven win. That gap is closing. A dedicated head-to-head against tirzepatide, called TRIUMPH-5, is underway in roughly 800 patients over 89 weeks and has not yet reported.
Reconstitution and Concentration Math
This is arithmetic, shown here purely to explain how peptide concentration works. It is not instructions, and it does not change anything about whether retatrutide can legally be sourced or used right now, which the section further down covers directly.
Concentration in milligrams per milliliter equals the vial’s total milligrams divided by however much bacteriostatic water is added. On a U-100 insulin syringe, 100 units equals 1 milliliter. The table below uses the 1, 2, 4, 8, and 12mg doses from the round-number protocol above, since that is the ladder most people will be calculating against.
10 mg/mL comes from either a 10mg vial mixed with 1mL of water, or a 30mg vial mixed with 3mL. 20 mg/mL comes from a 30mg vial mixed with 1.5mL. The asterisk matters, since at 10 mg/mL a 12mg dose works out to 120 units, more than a single U-100 syringe holds, which is why a more concentrated mix or a split draw is typically used at the higher doses.
📦 Supply Planning
Straight math on how long a single 30mg vial lasts at each weekly dose, no reconstitution guesswork required once you know your dose.
| 1mg / week | ~30 weeks (7 months) |
| 2mg / week | ~15 weeks (3.5 months) |
| 4mg / week | ~7.5 weeks (under 2 months) |
| 8mg / week | ~3.75 weeks (under a month) |
| 12mg / week | ~2.5 weeks |
💡 Pro tip: Label the vial or syringe with the concentration you mixed. Two vials at different concentrations look identical, and that mix-up is one of the most common real-world errors with any reconstituted peptide.
The mistakes that come up constantly with any peptide math include treating a vial’s total milligrams as a single dose, misreading syringe units at a different concentration than the one calculated, and skipping refrigeration on a compound that degrades without it.
Frequency, Timing, and Missed Doses
Once weekly, on a consistent day, matching the roughly 6-day half-life. Time of day does not appear to matter in the trials, though plenty of people prefer injecting at bedtime to sleep through early nausea. Rotating between the abdomen, thigh, and upper arm, at least an inch from the previous site, is standard practice.
GI symptoms tend to hit hardest in the first few days after any step up, then ease. Common approaches for making that stretch more tolerable include eating a small meal rather than injecting on a completely empty stomach, sticking to bland food for a day or two afterward, favoring smaller and more frequent meals over large ones, and skipping alcohol and greasy or heavily spiced food while a new dose settles in.
💡 Pro tip: Let a refrigerated vial sit at room temperature for about 30 minutes before injecting. A cold injection is more likely to sting or ache afterward.
Retatrutide has no published missed-dose guidance of its own, since it is not an approved drug with an official label. By analogy to semaglutide and tirzepatide, which share the same weekly, long-half-life design, the common pattern is to take a missed dose if several days remain before the next one is due and simply skip it if the next dose is close, without ever doubling up. Treat that as a reasonable inference from a similar drug class, not retatrutide-specific data.
Verified Sourcing
Everest GLP-3 RT, COA on Every Batch
Skip the guesswork on identity and purity. Every Everest batch is independently verified through Freedom Diagnostics, with the certificate posted right on the product page. Available in 10mg, 20mg, and 30mg vials, all supplied in 3mL.
Get GLP-3 RT → Save 10%Code BRAINFLOW takes 10% off the sale price. Sold for research use only.
Safety and Who Should Avoid It
Serious adverse events in the Phase 2 trial ran about 4% on placebo and 0 to 6% on retatrutide, not meaningfully different from placebo. The real burden sits in the common, dose-related GI symptoms covered above, plus a mild dose-dependent rise in resting heart rate that peaked around 24 weeks and eased afterward.
Retatrutide has not been tested in enough people for its own dedicated safety label, so the contraindications discussed for it are drawn from the same warnings that apply to the rest of the GLP-1 drug class, plus the exclusion criteria used in its own trials.
That list includes a personal or family history of medullary thyroid carcinoma or MEN2, since drugs in this class carry an FDA boxed warning based on findings in rodent studies, along with prior serious allergic reaction to a similar drug, and pregnancy. Relative cautions worth flagging to a doctor include a history of pancreatitis, severe gastroparesis, active gallbladder disease, and significant kidney or liver impairment.
Because retatrutide adds glucagon activity on top of GLP-1 and GIP, and glucagon can theoretically raise blood sugar and heart rate on its own, monitoring both is a reasonable extra step that dual or single-receptor drugs do not require in the same way.
Where Things Really Stand
Retatrutide is not FDA-approved for anything, and it is investigational. On July 23, 2026, Lilly announced it plans to file for approval, a Biologics License Application, in the first quarter of 2027. That is a filing plan, not an approval, and the FDA has not set any decision date. No brand name has been announced.
Five Phase 3 trials have reported positive results so far, TRIUMPH-4 in December 2025, TRANSCEND-T2D-1 in March 2026, TRIUMPH-1 in May 2026, and TRIUMPH-2 and TRIUMPH-3 in July 2026. A head-to-head trial against tirzepatide and a large long-term cardiovascular and kidney outcomes trial are both still running, with the outcomes trial not expected to finish before 2028 or 2029.
The distinction that matters most is this. Retatrutide is not approved for pharmacies to compound into a prescription product. Semaglutide and tirzepatide briefly became legal for pharmacies to compound because the FDA-approved versions of those drugs were on an official drug shortage list, which opened a specific legal exception.
Retatrutide has never been FDA-approved in the first place, and it has never appeared on that shortage list, so the exception that applied to the other two drugs was never available for this one. That is a real, meaningful restriction, and it means no pharmacy can legally compound it into something you’d pick up with a prescription.
That is a different question from whether a supplier can sell the compound itself. Research chemical suppliers sell retatrutide the same way they sell most unapproved peptides, labeled for laboratory and research use only, not for human consumption, without treatment claims attached.
In September 2025 the FDA sent warning letters to six companies, five in the United States and one in Germany, over how they were marketing retatrutide-labeled products specifically. That is a real, targeted enforcement signal worth knowing about. It is not evidence that selling the compound under research-use labeling is itself illegal, which is the same legal ground nearly every research peptide on the market sits on.
Where to Buy Retatrutide
Sourcing matters here as much as anywhere in this space, since retatrutide is a large, complex peptide, and knowing exactly what’s in the vial is worth confirming before anything else. Buy only from a supplier that publishes a real third-party certificate of analysis, not just a purity number with nothing behind it.
Our pick is Everest Peptides’ GLP-3 RT, their internal name for research-grade retatrutide. Every batch is third-party tested through Freedom Diagnostics, with purity guaranteed above 99% by HPLC and the certificate posted directly on the product page. It ships in a 3mL vial across three sizes, 10mg, 20mg, and 30mg.
The 10mg runs $69.99, currently on sale for $59.99. The 30mg runs $159.99, on sale for $149.99. Code BRAINFLOW takes another 10 percent off the sale price, landing around $53.99 for the 10mg and $134.99 for the 30mg.
What People Report
Treat this as anecdote only. In online communities discussing GLP-1 drugs generally, people who describe using research-market retatrutide almost universally start well below the trial doses, often 0.25 to 1mg, and move up slower than either official schedule. The appetite suppression gets described as strong even at low doses, sometimes stronger than what the same people experienced on semaglutide or tirzepatide.
GI side effects and dropout get mentioned more with retatrutide than with the approved drugs in this class, which lines up with the trial data above. People who move through the ladder faster than either official schedule report worse symptoms almost without exception, which tracks with why Lilly built the slower Phase 3 version in the first place.
The most common confusion is which titration ladder to follow, since both circulate online without context, and whether sourcing it is legal, which the section above answers directly. It is not.
Retatrutide FAQ
What is the starting dose of retatrutide?
In the current Phase 3 trials, everyone starts at 2mg weekly. The earlier Phase 2 trial used 1, 2, or 4mg as starting points across different arms.
What is the maximum dose?
12mg once weekly is the highest dose studied in every trial run so far.
How much weight can you lose on retatrutide?
In the Phase 2 trial, the 12mg group averaged 24.2% weight loss at 48 weeks. In the longer Phase 3 TRIUMPH-1 trial, the 12mg group averaged 28.3% at 80 weeks, and 30.3% in a two-year extension.
Is retatrutide FDA approved?
No. It remains investigational. Lilly has announced plans to file for approval in the first quarter of 2027, with no confirmed approval date.
Is retatrutide stronger than tirzepatide?
The trial numbers point that way, but no head-to-head trial between the two has reported yet, so this is a comparison across separate studies, not a proven result. A direct head-to-head, TRIUMPH-5, is underway.
Can I legally buy retatrutide right now?
Not from a pharmacy as a prescription product. Unlike semaglutide and tirzepatide, retatrutide was never on an FDA drug shortage list, so it never qualified for the compounding exception those two drugs used. It is sold by research suppliers as an unapproved research chemical, labeled not for human consumption, the same category most research peptides fall under. The FDA sent warning letters to specific sellers in September 2025 over marketing claims, which is why sourcing from a supplier with real third-party testing matters.
What are the side effects of retatrutide?
Mostly gastrointestinal, nausea, diarrhea, and vomiting, all of which rise with dose. See the side-effects table above for exact rates by dose from the TRANSCEND-T2D-1 trial.
How do you reconstitute retatrutide?
Divide the vial’s total milligrams by the milliliters of bacteriostatic water added to get the concentration in mg/mL. See the reconstitution table above for worked examples.
The Bottom Line
Retatrutide has one of the strongest clinical evidence bases of any drug in this space right now, five positive Phase 3 trials, weight loss pushing past a quarter of body weight at the top dose, and a filing plan on the calendar. It still is not something a pharmacy can legally hand you as a prescription. The titration schedules and results above are exactly what happened inside Lilly’s trials, and the sourcing information above reflects the research-chemical market as it exists today, not a promise about where FDA approval lands.
Sources
- Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023. NEJM
- Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes, a Phase 2 trial.” The Lancet, 2023.
- ClinicalTrials.gov. Phase 2 obesity trial protocol, NCT04881760. ClinicalTrials.gov
- ClinicalTrials.gov. TRIUMPH-1, NCT05929066.
- ClinicalTrials.gov. TRIUMPH-2, NCT05929079.
- ClinicalTrials.gov. TRIUMPH-3, NCT05882045.
- ClinicalTrials.gov. TRIUMPH-4, NCT05931367.
- ClinicalTrials.gov. TRIUMPH-5, NCT06662383.
- ClinicalTrials.gov. TRANSCEND-T2D-1, NCT06354660.
- ClinicalTrials.gov. TRIUMPH-Outcomes, NCT06383390.
- Eli Lilly and Company. Investor release, TRIUMPH-1 topline results, May 21, 2026. Lilly Investor Relations
- Eli Lilly and Company. Investor release, TRANSCEND-T2D-1 topline results, March 19, 2026.
- Eli Lilly and Company. Investor release, TRIUMPH-2 and TRIUMPH-3 topline results and BLA filing plan, July 23, 2026.
- Eli Lilly and Company. Investor release, TRIUMPH-4 topline results, December 11, 2025.
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. NEJM
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022.
- Eli Lilly and Company. SURMOUNT-5 head-to-head topline results, tirzepatide vs semaglutide, December 2024.
- U.S. Food and Drug Administration. Warning letters to compounders and manufacturers of retatrutide and related peptides, September 9, 2025.
- U.S. Food and Drug Administration. Guidance to state pharmacy boards on retatrutide compounding status, 2025.
- KFF Health News. “FDA Cracks Down On Unapproved Weight Loss Drug Popular Online.” October 14, 2025. KFF Health News
Retatrutide is investigational and not FDA-approved for any indication. All information here is for educational purposes only and is not medical advice.
Retatrutide is not approved for pharmacy compounding into a prescription product. Products referenced here are sold for research use only, not for human or animal consumption. Consult a qualified healthcare provider for guidance on weight management options currently available to you.
